COMUNICADO: Se presentan nuevos datos sobre Zonegran® (zonisamida) en el congreso de la Sociedad Europea de Neuropediatría (y 3)

8. Eisai Ltd 2013. Zonegran Summary of Product Characteristics [http://www.medicines.org.uk/emc/medicine/16240/SPC/Zonegran+25%2c+50%2c+100+mg+Hard+Capsules ] (última actualización febrero de 2013)

9. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25.

10. Pugliatti M et al. (2007). Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia, 48(12), 2224 - 2233.

Date of preparation: September 2013

Job code: Zonegran-UK2510b

CONTACTO: Consultas de los medios de comunicación: Eisai Europe Ltd:Cressida Robson/Charlotte Andrews, +44(0)7908 314 155/+44(0)7947 231 513,Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net; Tonic LifeCommunications: Frances Murphy/Nicola Lilley , +44(0)207 798 9262/+44 (0)207 798 9905 , frances.murphy@toniclc.com, nicola.lilley@toniclc.com

WhatsAppFacebookTwitterLinkedinBeloudBluesky